Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Similar presentations


Presentation on theme: "Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:"— Presentation transcript:

1 Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / ) Table 1. Baseline characteristics of study participants according to baseline CKD status

2 Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / ) Table 1 (continued). Baseline characteristics of study participants according to baseline CKD status

3 Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / ) Table 2. Baseline characteristics of study participants by baseline CKD status and treatment arm

4 Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / ) Table 2 (continued). Baseline characteristics of study participants by baseline CKD status and treatment arm

5 Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / ) Fig. 1. Lipid values with standard and intensive lipid therapy in CKD and non-CKD study participants. a Total cholesterol levels over time by baseline CKD status and lipid arm. b Triglyceride levels over time by baseline CKD status and lipid arm. c LDL-C levels over time by baseline CKD status and lipid arm. d HDL-C levels over time by baseline CKD status and lipid arm.

6 Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / ) Fig. 2. Rates of primary and secondary outcomes according to CKD status at baseline among participants in the lipid arm of the ACCORD study.

7 Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / ) Fig. 3. Rates for the primary and secondary outcomes by treatment group (intensive vs. standard) in patients with CKD (a) and without CKD (b) at baseline.

8 Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study Papademetriou et al. Am J Nephrol 2017;45:   (DOI: / ) Table 3. Adverse events by treatment group and CKD status


Download ppt "Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:"

Similar presentations


Ads by Google